Kairos Pharma Ltd. (NYSE American: KAPA) provided a mid-year 2026 update, highlighting its strategy to expand its oncology pipeline through the proposed acquisition of worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor from Celyn Therapeutics. CL-741 targets EGFR-mutated lung cancer and other cancers, and the company expects it to complement its existing portfolio, which includes ENV-105, KROS-201, KROS-102 and ENV-205.
According to the update, Kairos plans to initiate a Phase 1 study of CL-741 and advance ongoing clinical trials of ENV-105 in prostate cancer and non-small cell lung cancer. The company also aims to present data at scientific meetings and pursue pharmaceutical collaborations. Notably, Kairos has secured more than $8 million in non-dilutive funding to support development of its preclinical and clinical programs. The full press release is available at https://ibn.fm/WuBOf.
ENV-105, the company's lead candidate, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. It is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. Kairos Pharma utilizes structural biology to overcome drug resistance and immune suppression in cancer, and is based in Los Angeles, California.
The addition of CL-741 represents a significant expansion of Kairos's pipeline, potentially addressing a large unmet need in EGFR-mutated lung cancer, where resistance to existing therapies often develops. The company's focus on reversing drug resistance and restoring effectiveness of standard therapies could offer new options for patients with limited alternatives.
Investors can find the latest news and updates relating to KAPA in the company's newsroom at https://ibn.fm/KAPA. The company noted that as of the date of the press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
